|
|
This activity is provided by the Network for Continuing Medical Education.
This activity is supported by an educational grant from the sanofi-aventis Group.
|
 |
INTRODUCTION AND PROGRAM DESCRIPTION Please note that the course is accredited only for physicians (MD, DO, or equivalent). All other participants receive a certificate of completion. In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Essential Areas and Policies regarding commercial support, participants are advised that 1 or more presentations in this continuing medical education activity may contain references to off-label or unapproved uses of drugs or devices. Participants should note that the use of these agents outside current approved labeling is considered experimental and are advised to consult prescribing information for these products. This CME activity was planned and produced in accordance with the ACCME Essential Areas and Policies.
Learning Objectives After completing this activity, participants should be able to
Accreditation and Designation of Credit The Network for Continuing Medical Education (NCME) is accredited by the ACCME to provide continuing medical education for physicians. NCME designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Disclosure Policy NCME requires that CME faculty disclose, during the planning of an activity, the existence of any personal financial or other relationships they or their spouses/partners have with the commercial supporter of the activity or with the manufacturer of any commercial product or service discussed in the activity. Off-label Discussion This CME activity may include discussions regarding the use of medications that may be outside of the approved labeling for these products. Physicians should consult the current prescribing information for these products. NCME requires faculty members to disclose that a product is not yet labeled for the use under discussion or to state that the product is still investigational. Faculty Disclosures and Biographies Louis J. Aronne, MD, FACP Louis J. Aronne, MD, FACP, is a clinical professor of medicine at Weill Medical College of Cornell University and has an adjunct appointment at Columbia University College of Physicians and Surgeons in New York. A leading authority on obesity and its treatment, Dr Aronne also is director of the Comprehensive Weight Control Program, a state-of-the-art, multidisciplinary obesity research and treatment program at New York-Presbyterian Hospital. In addition, he is president of the North American Association for the Study of Obesity (NAASO) and a fellow of the American College of Physicians. Dr Aronne has authored or coauthored more than 40 papers and book chapters on obesity and edited the National Institutes of Health's Practical Guide to the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. He also is a consultant to the VA Weight Management/Physical Activity Executive Council. Dr Aronne has lectured widely on obesity management at national medical society meetings and medical institutions. In addition, he has served as principal investigator or coinvestigator for a number of industry-supported research studies. A graduate of the Johns Hopkins University School of Medicine, he graduated Phi Beta Kappa from Trinity College with a BS in biochemistry. Dr Aronne has won several awards for medical teaching, including the Leo M. Davidoff Society Prize from Albert Einstein College of Medicine and the Elliot Hochstein Teaching Award from Weill Medical College of Cornell University. He also is a member of the Alpha Omega Alpha medical honor society. Daniel J. Rader, MD Daniel J. Rader, MD, is the Cooper-McClure Associate Professor of Medicine, Pathology, and Pharmacology at the University of Pennsylvania School of Medicine in Philadelphia. Dr Rader also is director of the Preventive Cardiovascular Medicine and Lipid Clinic, director of the General Clinical Research Center, and associate director of the Institute for Translational Medicine and Therapeutics at the university. He also has leadership roles in the university’s Cardiovascular Institute and Institute for Diabetes, Obesity, and Metabolism. A graduate of the Medical College of Pennsylvania, he received his undergraduate degree from Lehigh University. He completed an internship and residency in internal medicine at Yale-New Haven Hospital, followed by a year as a chief resident. In 1988, he began a fellowship in lipid metabolism at the Molecular Disease Branch of the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH). Subsequently, he was appointed to a staff scientist position and spent 5½ years at the NIH. In 1994, he was recruited to the University of Pennsylvania.
Dr Rader’s basic research laboratory focuses on genetic and pharmacologic regulation of lipoprotein metabolism and atherosclerosis, and he directs a translational research program focusing on human genetics of lipid disorders and atherosclerosis and novel approaches to treatment of dyslipidemia and regression of atherosclerosis. He has a particular interest in high-density lipoprotein (HDL) metabolism, factors and genes involved in its regulation, the causal nature of the relationship of HDL metabolism to atherosclerosis, and novel approaches to targeting HDL metabolism and reverse cholesterol transport in the treatment, prevention, and regression of atherosclerosis.
Dr Rader is a member of the American Society for Clinical Investigation and is current chair of the Scientific Board of the Stanley Sarnoff Endowment for Cardiovascular Science. He is a past established investigator of the American Heart Association, a recipient of a Burroughs Wellcome Fund Clinical Scientist Award in Translational Research, and a Doris Duke Charitable Foundation Distinguished Clinical Scientist Award.
He is a member of the editorial boards of the American Journal of Physiology (Endocrinology and Metabolism), Arteriosclerosis, Thrombosis, and Vascular Biology; Circulation; Circulation Research; and Trends in Molecular Medicine. Dr Rader has authored more than 250 peer-reviewed publications, review articles, and book chapters, including chapters on lipoprotein disorders for Harrison’s Principles of Internal Medicine, Topol’s Textbook of Cardiovascular Medicine, and the Nelson Textbook of Pediatrics. He is frequently invited to speak, nationally and internationally, on his basic and translational research in lipoprotein metabolism and atherosclerosis and on clinical topics such as novel approaches to cardiovascular risk assessment and management of lipid disorders. Sidney C. Smith, Jr, MD, FACP Sidney C. Smith, Jr, MD, is a professor of medicine and director of the Center for Cardiovascular Science and Medicine at the University of North Carolina at Chapel Hill. He received his medical degree from Yale University in New Haven, Connecticut, and completed a residency in internal medicine and a fellowship in cardiology at Harvard Medical School/Peter Bent Brigham Hospital in Boston, Massachusetts. Prior to joining the faculty of the University of North Carolina, Dr Smith was a clinical professor of medicine at the University of California, San Diego, and director of the San Diego Cardiac Center at Sharp Healthcare. He also served as director of the Cardiovascular Laboratories at the University of Colorado. From 1994-2001, he served as chief of cardiology at the University of North Carolina.
From 1995-1996, Dr Smith was national president of the American Heart Association (AHA) and from 2001-2003 was the first chief science officer of the AHA. His service with the AHA spans 2 decades and includes work at all levels of the organization and with 3 different AHA affiliates. He has been a member of several national committees of the American College of Cardiology (ACC) and has been active in the development of ACC/AHA practice guidelines for the past 15 years. Currently, he serves as chair of the ACC/AHA Committee to Revise Guidelines for Percutaneous Coronary Intervention (PCI) and chair of the ACC/AHA Task Force on Practice Guidelines.
Dr Smith is a member of the editorial boards of the American Heart Journal, Circulation, the Journal of the American College of Cardiology, the Journal of Interventional Cardiology, and the American College of Cardiology Education and Learning Program. He also served on the medical advisory board for the Time-Life medical series. Author of more than 200 articles and book chapters, Dr Smith lectures regularly at scientific meetings and is a frequent invited speaker. He has spoken widely about heart disease and stroke in interviews with CNN, CBS, NBC, and many national newspapers. Dr Smith currently serves as chairman of the scientific advisory board of the World Heart Federation.
In 1993, Dr Smith was honored as the AHA’s Physician of the Year and in 1996 received the association’s Distinguished National Leadership Award. Yearly since 1998, he has been elected to “Best Doctors in America.” In 2000, he was awarded the prestigious Gold Heart Award by the AHA. In 2003, he received the award of Special Recognition from the National Heart, Lung, and Blood Institute (NHLBI).
The focus of Dr Smith’s academic work has been on lipoprotein abnormalities, reperfusion therapies for acute myocardial infarction, medical management of unstable angina pectoris, and the metabolic syndrome. He is currently evaluating the role of guidelines and performance measures to improve health care delivery efforts in the treatment of cardiovascular disease. Instructions to Participants Course participants must view all audio/slide/video presentations and complete the course evaluation in order to receive continuing medical education credit. No fees are charged to participate in the program or to receive the certificate. Full instructions are available on the user instructions page. Disclaimer The opinions expressed herein are those of the faculty and do not necessarily represent the views of the grantor, accrediting body, or publisher. Please review complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients. Medicine is a constantly changing science, and clearly established therapies are not always available for every condition. New research findings necessitate continual changes in drug and treatment therapies. Reasonable efforts have been made to provide up-to-date, accurate information that is within generally accepted medical standards at the time of publication. However, as medical science is ever evolving, and human error is always possible, the educational supporter, provider, and publisher (or any other involved party) do not guarantee total accuracy or comprehensiveness of the information in this article, and they are not responsible for omissions or errors, or the results of using information provided in this course. Participants should confirm the accuracy of the information in this activity from other sources. In particular, all drug doses, indications, and contraindications should be confirmed in package inserts. Click here to view minimum system requirements.
|
